Annals of Oncology 15:257-260, 2004
© 2004 European Society for Medical Oncology
Original Paper |
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
Received 29 May 2003; revised 5 August 2003; accepted 30 September 2003Background:
The growth pattern of malignant pleural mesothelioma makes the use of RECIST (response evaluation criteria in solid tumours) response criteria difficult. We have developed and validated Modified RECIST criteria adapted to the growth pattern of malignant pleural mesothelioma.
Patients and methods:
We evaluated 73 patients from two clinical trials of cisplatin/gemcitabine chemotherapy in malignant pleural mesothelioma. Tumour thickness perpendicular to the chest wall or mediastinum was measured in two positions at three separate levels on thoracic CT scans. The sum of the six measurements defined a pleural unidimensional measure. Bidimensionally measureable lesions were measured unidimensionally as for RECIST. All measurements were added to obtain the total tumour measurement. A reduction of at least 30% on two occasions 4 weeks apart defined a partial response; an increase of 20% over the nadir measurement, progressive disease. The validity of the modified criteria was gauged by evaluating survival and pulmonary function.
Results:
Response according to these criteria predicted for superior survival (15.1 versus 8.9 months; P = 0.03) and forced vital capacity (FVC) increase during treatment (P <0.0001). A significant correlation between change in linear tumour measurement and FVC was seen (R = 0.63; P = 0.0001).
Conclusion:
These Modified RECIST criteria for tumour response correlate with survival and lung function and can be used to measure outcome in pleural mesothelioma.
1 Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA 6009; 2 Department of Medicine, University of Western Australia, Nedlands, WA 6009, Australia
Key words: chemotherapy, clinical trials, mesothelioma, RECIST, response criteria, validation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. A. Janne, G. R. Simon, C. J. Langer, R. N. Taub, A. Dowlati, P. Fidias, M. Monberg, C. Obasaju, and H. Kindler Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy-Naive Malignant Pleural Mesothelioma J. Clin. Oncol., March 20, 2008; 26(9): 1465 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Castagneto, M. Botta, E. Aitini, F. Spigno, D. Degiovanni, O. Alabiso, M. Serra, A. Muzio, R. Carbone, R. Buosi, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM) Ann. Onc., February 1, 2008; 19(2): 370 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Ceresoli, A. Chiti, and A. Santoro 11C-Labeled Methionine and Evaluation of Malignant Pleural Mesothelioma N. Engl. J. Med., November 8, 2007; 357(19): 1982 - 1984. [Full Text] [PDF]
|
|
|
|
 |
|
 British Thoracic Society Standards of Care Committ BTS statement on malignant mesothelioma in the UK, 2007 Thorax, November 1, 2007; 62(Suppl_2): ii1 - ii19. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Francis, M. J. Byrne, A. A. van der Schaaf, J. A. Boucek, A. K. Nowak, M. Phillips, R. Price, A. P. Patrikeos, A. W. Musk, and M. J. Millward Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans J. Nucl. Med., September 1, 2007; 48(9): 1449 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Clayton, J. P. Mitchell, J. Court, M. D. Mason, and Z. Tabi Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2 Cancer Res., August 1, 2007; 67(15): 7458 - 7466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Sterman, A. Recio, R. G. Carroll, C. T. Gillespie, A. Haas, A. Vachani, V. Kapoor, J. Sun, R. Hodinka, J. L. Brown, et al. A Phase I Clinical Trial of Single-Dose Intrapleural IFN-{beta} Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses Clin. Cancer Res., August 1, 2007; 13(15): 4456 - 4466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Garland, C. Rankin, D. R. Gandara, S. E. Rivkin, K. M. Scott, R. B. Nagle, A. J.P. Klein-Szanto, J. R. Testa, D. A. Altomare, and E. C. Borden Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study J. Clin. Oncol., June 10, 2007; 25(17): 2406 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Ceresoli, A. Chiti, P. A. Zucali, M. Rodari, R. F. Lutman, S. Salamina, M. Incarbone, M. Alloisio, and A. Santoro Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose J. Clin. Oncol., October 1, 2006; 24(28): 4587 - 4593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Jaffe Measures of Response: RECIST, WHO, and New Alternatives J. Clin. Oncol., July 10, 2006; 24(20): 3245 - 3251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Francart, C. Legrand, R. Sylvester, M. Van Glabbeke, J. P. van Meerbeeck, and A. Robert Progression-Free Survival Rate As Primary End Point for Phase II Cancer Clinical Trials: Application to Mesothelioma--The EORTC Lung Cancer Group J. Clin. Oncol., July 1, 2006; 24(19): 3007 - 3012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Schwartz, J. A. C. Colville, M. S. Ginsberg, L. Wang, M. Mazumdar, J. Kalaigian, H. Hricak, D. Ilson, and G. K. Schwartz Measuring tumor response and shape change on CT: esophageal cancer as a paradigm Ann. Onc., June 1, 2006; 17(6): 1018 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Opitz, P. Kestenholz, D. Lardinois, M. Muller, V. Rousson, D. Schneiter, R. Stahel, and W. Weder Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 579 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Galanis, J. C. Buckner, M. J. Maurer, R. Sykora, R. Castillo, K. V. Ballman, B. J. Erickson, and for the North central cancer treatment Group Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods Neuro-oncol, April 1, 2006; 8(2): 156 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Armato III, J. L. Ogarek, A. Starkey, N. J. Vogelzang, H. L. Kindler, M. Kocherginsky, and H. MacMahon Variability in mesothelioma tumor response classification. Am. J. Roentgenol., April 1, 2006; 186(4): 1000 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Ceresoli, P. A. Zucali, A. G. Favaretto, F. Grossi, P. Bidoli, G. Del Conte, A. Ceribelli, A. Bearz, E. Morenghi, R. Cavina, et al. Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma J. Clin. Oncol., March 20, 2006; 24(9): 1443 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. van Meerbeeck, R. Gaafar, C. Manegold, R. J. Van Klaveren, E. A. Van Marck, M. Vincent, C. Legrand, A. Bottomley, C. Debruyne, and G. Giaccone Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada J. Clin. Oncol., October 1, 2005; 23(28): 6881 - 6889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Nowak and M. J. Byrne Cisplatin and gemcitabine in malignant mesothelioma Ann. Onc., October 1, 2005; 16(10): 1711 - 1711. [Full Text] [PDF]
|
|
|
|
|
|
C. Lu, R. Perez-Soler, B. Piperdi, G. L. Walsh, S. G. Swisher, W. R. Smythe, H. J. Shin, J. Y. Ro, L. Feng, M. Truong, et al. Phase II Study of a Liposome-Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally and Pathologic Response Rates in Patients With Malignant Pleural Mesothelioma J. Clin. Oncol., May 20, 2005; 23(15): 3495 - 3501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. C. Steele and A. Klabatsa Chemotherapy options and new advances in malignant pleural mesothelioma Ann. Onc., March 1, 2005; 16(3): 345 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Nowak, M. R. Stockler, and M. J. Byrne Assessing Quality of Life During Chemotherapy for Pleural Mesothelioma: Feasibility, Validity, and Results of Using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module J. Clin. Oncol., August 1, 2004; 22(15): 3172 - 3180. [Abstract] [Full Text] [PDF]
|
|